Avenue Therapeutics director Jay Kranzler sells 136 in stock
ATXI Stock | USD 2.06 0.02 0.98% |
Under 52% of Avenue Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Avenue Therapeutics stock suggests that many investors are impartial at this time. Avenue Therapeutics' investing sentiment shows overall attitude of investors towards Avenue Therapeutics.
Avenue |
Avenue Therapeutics director Jay Kranzler sells 136 in stock
Read at investing.com
Avenue Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Avenue Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avenue Therapeutics Fundamental Analysis
We analyze Avenue Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avenue Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avenue Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Avenue Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Avenue Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avenue Therapeutics stock to make a market-neutral strategy. Peer analysis of Avenue Therapeutics could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics with similar companies.
Peers
Avenue Therapeutics Related Equities
WINT | Windtree Therapeutics | 8.93 | ||||
HOTH | Hoth Therapeutics | 3.75 | ||||
BDRX | Biodexa Pharmaceticals | 2.71 | ||||
VRAX | Virax Biolabs | 2.48 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
PALI | Palisade Bio | 0.83 | ||||
NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
CNSP | Cns Pharmaceuticals | 7.69 | ||||
ALLR | Allarity Therapeutics | 10.48 |
Complementary Tools for Avenue Stock analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |